Eupraxia Pharmaceuticals (EPRX) Change in Receivables (2023 - 2026)
Eupraxia Pharmaceuticals' (EPRX) quarterly Change in Receivables came in at $23964.0 in Q1 2026, up 376.24% year-on-year from $5031.9 in Q1 2025, and down 92.84% on a QoQ basis from $334631.0 in Q4 2025.
Eupraxia Pharmaceuticals (EPRX) Change in Receivables (2023 - 2026) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has 4 years of Change in Receivables data on file, last reported at $23964.0 in Q1 2026.
- On a quarterly basis, Change in Receivables rose 376.24% year-over-year to $23964.0 in Q1 2026; TTM through Mar 2026 was $464088.0, a 514.58% increase from a year earlier, with the FY2025 full-year figure at $431449.0, up 325.54% from the prior year.
- Change in Receivables for Q1 2026 stood at $23964.0, down from $334631.0 in the prior quarter.
- Over the last five years, Change in Receivables for EPRX reached as high as $334631.0 in Q4 2025 and fell as low as -$17845.0 in Q3 2023.
- Historically, Change in Receivables has averaged $50808.6 across 4 years, with a median of $20085.0 in 2024.
- On a YoY basis, Change in Receivables climbed as much as 1566.07% in 2025 and fell as far as 150.43% in 2025.
- Year by year, Change in Receivables stood at $83213.0 in 2023, then plunged by 75.86% to $20085.0 in 2024, then soared by 1566.07% to $334631.0 in 2025, then tumbled by 92.84% to $23964.0 in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were $23964.0 in Q1 2026, $334631.0 in Q4 2025, and -$7278.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Eupraxia Pharmaceuticals | 357.29 Mn | 355.69 Mn | - | 23,964.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23,964.00 |
| Mar 31, 2026 | 23,964.00 |
| Dec 31, 2025 | 334,631.00 |
| Dec 31, 2025 | 334,631.00 |
| Sep 30, 2025 | -7,278.00 |
| Sep 30, 2025 | -7,278.00 |
| Jun 30, 2025 | 112,771.00 |
| Jun 30, 2025 | 112,771.00 |
| Mar 31, 2025 | -8,675.00 |
| Mar 31, 2025 | -8,675.00 |
| Dec 31, 2024 | 20,085.00 |
| Dec 31, 2024 | 20,085.00 |
| Sep 30, 2024 | 50,432.00 |
| Sep 30, 2024 | 50,432.00 |
| Jun 30, 2024 | 13,671.00 |
| Jun 30, 2024 | 13,671.00 |
| Mar 31, 2024 | 17,201.00 |
| Mar 31, 2024 | 17,201.00 |
| Dec 31, 2023 | 83,213.00 |
| Dec 31, 2023 | 83,213.00 |